Create a narrative

Vir Biotechnology Community

NasdaqGS:VIR Community

1 Narratives written by author
0 Comments on narratives written by author
11 Fair Values set on narratives written by author

Vir Biotechnology

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 8 Analysts

Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success

Key Takeaways ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams. Restructuring to reduce expenses and strategic capital allocation enhance financial stability, ensuring long-term sustainability and support for clinical development.

US$17.63

FV

74.1% undervalued

40.65%

Revenue growth p.a.

0

0

11

15 days ago